CARDDI-BEL: D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study

Sponsor
AZ Sint-Jan AV (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04784039
Collaborator
(none)
1,368
2
13

Study Details

Study Description

Brief Summary

This trial aims at evaluating the number of thromboembolic events post cardioversion in patients receiving a direct current cardioversion with either prior transesophageal echocardiography or D-Dimer (DD) analysis.

Patients in need of a direct current cardioversion (DCCV), meeting the criteria for DCCV with prior transesophageal echocardiography (TEE), will be asked to participate in the CARDDI-BEL study.

Patients will be randomized on a 1:1 ratio to the TEE-group or DD-group. Patients in the TEE-group will receive TEE prior to cardioversion to exclude left atrial thrombus according to current guidelines [1]. In patients randomized to the DD-group, D-Dimer will be analyzed (cut-off defined by DDage). If the DDage > 10x patient's age, the analysis is suggestive for the presence of left atrial thrombus and the cardioversion will be performed with prior TEE. In case of negative DDage, no TEE will be used in the DD-group.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Transesophageal echocardiography
  • Diagnostic Test: D-Dimer analysis
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1368 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: TEE-group

Diagnostic Test: Transesophageal echocardiography
Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE

Active Comparator: DD-group

Diagnostic Test: D-Dimer analysis
Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion

Outcome Measures

Primary Outcome Measures

  1. Incidence in thromboembolic events between both groups after 4 weeks follow-up [up to 4 weeks after cardioversion]

    The number of thromboembolic events (stroke, transient ischemic attack, ...) in the TEE and DD-group will be compared

Secondary Outcome Measures

  1. Correlation between D-Dimer-value (ng/L) and number of thrombi visible on TEE [Procedure (At time of cardioversion)]

  2. Correlation of DD-value (ng/L) with flow velocity (m/s) in case of spontaneous contrast or suspicion of thrombus in left atrial appendage [Procedure (At time of cardioversion)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients older than 18 years

  • Patients with non-valvular atrial fibrillation scheduled for direct current cardioversion with prior TEE according to current guidelines

  • Patients willing to sign informed consent

Exclusion Criteria:
  • Cardiac surgery within the previous 90 days.

  • Coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days.

  • Significant congenital anomaly or other medical problem that in the opinion of the investigator would preclude enrollment

  • History of blood clotting disease or bleeding abnormalities.

  • Patients with valve implants

  • Women who are pregnant

  • Aortic aneurysm or dissection

  • Documented history of deep vein thrombosis within the last 6 months

  • Documented history of pulmonary embolism within the last 6 months

  • Unwilling or unable to provide informed consent.

  • Recent transient ischemic attack or stroke (90 days)

  • Instable angina

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • AZ Sint-Jan AV

Investigators

  • Principal Investigator: Sébastien Knecht, MD, PhD, AZ Sint-Jan AV

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sebastien Knecht, Principal Investigator, AZ Sint-Jan AV
ClinicalTrials.gov Identifier:
NCT04784039
Other Study ID Numbers:
  • Version 1.0, 25 February 2021
First Posted:
Mar 5, 2021
Last Update Posted:
Mar 5, 2021
Last Verified:
Mar 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 5, 2021